Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled dose-ranging study of ALXN2050 in proliferative lupus nephritis or IgA nephropathy
MOH_2022-01-12_010547Phase 2Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vemircopan in lupus nephritis (LN) and IgA nephropathy (IgAN) (6 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Efficacy in reducing proteinuria. Started Nov 2021; status: recruiting.
02
Drugs
vemircopan
03
Conditions
lupus nephritis (LN)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on MOH_2022-01-12_010547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-12_010547.